Lynn is CEO and founder of STALICLA. Driven by her lifelong involvement with the autism community, Lynn has instituted a paradigm shift in the neurodevelopmental disorder (NDD) drug discovery space by pioneering the creation of the first NDD specific precision medicine discovery platform. Lynn has assembled a world-class cross functional team of drug developers, clinicians and data scientists in STALICLA’s Geneva (Drug Development) and Barcelona (Discovery and Data Science) units as well as a unique collaborative network of academic leading research centers & hospitals in the US. Lynn has authored and co-authored 7 patents and is the recipient of a brain Foundation award for “outstanding leadership towards the advancement of treatments for patients with Neurodevelopmental disorders”.
A biotech entrepreneur, Lynn has a strong business background, starting her career at the World Economic Forum and with a leading Swiss venture capital firm. Before founding STALICLA, she was Head of Partnerships at the University of Geneva and has held senior business development positions at several entities including IFJ AG. EPFL Innovation Park and Tech Tour. Lynn holds master’s degrees in economic history and political sciences from ICP Paris, in corporate communication from NEOMA Business School and in drug discovery and clinical development from the University of Geneva Faculty of Medicine.
Office of the CEO includes: Marco Minoia MBA-Ph.D., Jean-Marc Hyvelin Ph.D., Monika Lacna M.A, Liliane Bizimana BA (scroll down for profiles)
The DDS unit leverages on a first in class computational biology machine learning platform to identify specific biological subgroups and bring precision medicine to patients living with Neuro Developmental Disorders. DDS comprises 11 highly skilled members including computational biologists, human geneticists, data scientists, chemo-informaticians and developers.
Emre has 15 years of experience in computational data analysis with an emphasis on translational systems medicine, disease bioinformatics and network pharmacology. He spent several years as a postdoctoral scholar at Harvard Medical School and Northeastern University in the USA, where he pioneered the development of in silico drug efficacy screening using computational modeling of integrative multi-omics data. He was an investigator in EU funded consortia projects for drug toxicity and efficacy modeling during his appointments at the Research Programme in Biomedical Informatics at the Hospital del Mar Research Institute (IMIM) in Spain and at the Pharmacology & Personalised Medicine department at Maastricht University in the Netherlands. He is an alumni of "From Science to Business" program of ESADE Business & Law School in Barcelona. He has a track record of scientific innovation, with more than 40 peer-reviewed publications and has authored/co-authored 4 patents.
Laura brings 15 years of experience in computational biology research with a solid background in autism genetics, as well as a strong personal involvement and commitment with the autism community. After graduating with honors in Biotechnology, she obtained a M.S. degree in Proteomics and a Ph.D. in Bioinformatics at the University of Barcelona. She conducted her Ph.D. research work at the Barcelona Supercomputing Center, which resulted in important contributions to the field of Computational Structural Biology. Before joining STALICLA, Laura spent 5 years as a postdoctoral researcher at the David Geffen School of Medicine at the University of California Los Angeles (UCLA), where she co-led large-scale whole-genome sequencing analyses resulting in the identification of several novel autism risk genes with an unprecedented contribution from inherited risk variation. Since joining STALICLA in 2019, Laura has co-authored 4 patent applications focused on advancing precision medicine for patients with neurodevelopmental disorders.
The Management team of the DDS unit is supported by: Valeria De Caprio (Office Manager)
Bringing drug candidates to clinical stage through late pre-clinical development and regulatory entry preparation. DDU comprises 17 highly skilled members.
Adj. Professor of Neurology and Neurosurgery with global recognition in Neurodevelopmental Disorders and Neurodegenerative Diseases. Reached successful NDAs (New Drug Approval) for several drug candidates in CNS. He has over 25 years of experience in industry and has held multiple senior management roles in clinical neuroscience and biomarker development.
Xavier Liogier D’Ardhuy
Ph.D. - Neuropsychologist, Drug Development Advisor in NDDs
Former CTD at STALICLA (2019-2020). Xavier has 20 years of experience in NDD early clinical development including Autism, Down Syndrome and Schizophrenia.
Oliver brings more than 15 years of experience in non-clinical and early clinical drug development. In previous roles as Global Project Director and Non-Clinical Development & Phase 1 Project Director at PregLem and Gedeon Richter, Oliver substantially contributed to the successful registration of fibroid treatment Esmya®. More recently, as ObsEva’s Vice President of Non-Clinical Development and Phase 1, he brought a number of treatment candidates to IND stage in the US, Europe or China and supported several development programs up to marketing authorization application. His interests include all aspects of non-clinical, early clinical and translational drug development. Oliver holds a doctorate in Veterinary Medicine from the University of Munich and post-graduate degrees in biostatistics, toxicology and public health. He is the author or co-author of more than 20 peer-reviewed publications and 5 patents.
Richard brings more than 15 years of experience in the development and operational implementation of multidisciplinary innovative projects. After his PhD, he spent 6 years in Japan and Germany working on the development of efficient materials for organic photovoltaics. He then joined Adocia, a clinical-stage biotech company, and rapidly evolved to become the Director of Chemistry while holding Project Leader positions. He actively participated in the growth of the company and launched the activities and collaborations leading to the generation of a library of more than 500 hit compounds and to the industrial GMP manufacturing of 5 lead candidates. As a Project Leader, Richard has brought three projects from proof of concept into clinical Phase I/II. Richard holds a Ph.D. in organic and synthetic polymer chemistry from North Carolina State University (NCSU). He is the author/co-author of 19 publications and inventor/co-inventor of more than 40 patent applications. Richard completed an Executive MBA at EM Lyon Business School.
Passionate about Neuroscience, Magdalena has over 15 years of experience in the strategic and operational planning and execution of large clinical development programs (from FIH up to market launch, including PoC, Phase 2b/DRF and registration-relevant and post-marketing Clinical Pharmacology studies). Magdalena previously provided leadership, project management, and program oversight over 10 years to the global portfolio of Novartis, in support of successful NDA/MAA submission, approval and launch of Xolair®, Gilenya®, Mayzent® expanding the company’s neuroscience portfolio and addressing a high unmet medical need. Most recently, Magdalena led clinical research activities with a focus on clinical pharmacology at GlaxoSmithKline for clinical development projects, marketed products (regulatory defence) and during the evaluation of new product opportunities. Magdalena holds master degrees in Biomedical Science and in Public Health, coupled with postgraduate courses from Faculty of Medicine and Faculty of Pharmaceutical Science in Geneva and Toulouse.
Results-driven Finance Executive with over 15 years of leadership experience as Auditor then CFO in a wide range of industries (e. g. Real Estate construction, Fine-Art transport and storage, Fitness, Audit and Hotel Industry), with public and private entities of all sizes, François possesses a wide range of skills he has applied with success with many SMEs. Autonomous and independent François has widely recognised human and technical skills, specifically within finance function implementation and improvement, ERP development and personalisation, IT systems and internal processes automation and improvement. François graduated from the Hotel School of Lausanne, HEC-Lausanne and holds the Federal Diploma as a Chartered Accountant.
Founder Associate - Project Manager
Project manager with 10 years of experience in worldwide academic research institutions and hands-on in fundraising and business development in the biotech start-up space. Marco holds a PhD in molecular biology and an MBA in Business and Administration.
Head of Partnerships and Project Management (Ad Interim)
Former COO at STALICLA (2017-2020) – Seasoned Operation and Project Manager with 10 years of experience in worldwide academic research laboratories and more than 10 years in the field of Pharmaceutical and Biotech Environment. Instrumental in directing and improving processes, enhancing productivity, and implementing technology solutions in various drug/medtech development projects. He is skilled in spearheading research and innovation activity in corporate settings and has a strong ability to develop and maintain partnerships with key internal and external stakeholders. Jean-Marc holds a Ph.D. in Cellular Physiology and has authored 44+ articles and several patents.
Back Office Operations and HR
More than 20 years of experience in project management in different geographical regions and cultures, including Europe, Asia, Middle East and North Africa. Monika holds a Master Degree in Management and Marketing of Enterprises.
A diligent resource manager with over 10 years experience in all aspects of administrative, budgetary and organizational support functions in the financial sector and as an international civil servant in Africa. Liliane holds a university degree in economics and law from Université Lyon II and Professional BA in Organizational and cross functional Management from IAE LYON.